| P2093 | author name string | Al B. Benson | |
| | Max Vergo | |
| P2860 | cites work | Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 |
| | Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 |
| | A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer | Q33387432 |
| | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 |
| | Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group | Q39332358 |
| | Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial | Q42285544 |
| | Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 |
| | Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group | Q80704657 |
| | Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer | Q85026066 |
| P433 | issue | Suppl 2 | |
| P304 | page(s) | S2-S5 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Gastrointestinal cancer research : GCR | Q27722152 |
| P1476 | title | An Update in Advanced Gastric Cancer: 2009 | |